INDICATION

IMLYGIC® is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. IMLYGIC® has not been shown to improve overall survival or have an effect on visceral metastases.

<table>
<thead>
<tr>
<th>Item</th>
<th>Revenue Code</th>
<th>Coding Information (HCPCS/CPT/ICD-10-CM)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMLYGIC®</td>
<td>Medicare: 0636, drugs requiring detailed coding</td>
<td>J9325, injection, talimogene laherparepvec, 1 million plaque forming units (PFU)</td>
<td>Code effective for dates of service on or after 1/1/2017. IMLYGIC® is still eligible for separate payment under Medicare under the Hospital Outpatient Prospective Payment System (OPPS). C9472 should no longer be submitted for claims with dates of service on or after 1/1/2017. National Drug Code (NDC) billing requirements may vary by payer. The NDC numbers for IMLYGIC® in the 11-digit format, are as follows: - 1 million PFU per 1 mL vial (10^6 PFU/mL) for the initial dose only: 55513-0078-01 - 100 million PFU per 1 mL vial (10^8 PFU/mL) for the second and subsequent doses: 55513-0079-01.</td>
</tr>
<tr>
<td>Administration</td>
<td>Appropriate revenue code for the cost center in which the service is performed</td>
<td>96405, chemotherapy administration; intralesional, up to and including 7 lesions OR 96406, chemotherapy administration; intralesional, more than 7 lesions</td>
<td>If ultrasound guidance is used, the following administration code may also be appropriate: 76942, ultrasonic guidance for needle placement leg, biopsy, aspiration, injection, localization device, imaging supervision and interpretation.</td>
</tr>
<tr>
<td>Diagnosis/Condition</td>
<td>N/A</td>
<td>Appropriate ICD-10-CM code(s) for patient condition</td>
<td>Examples of ICD-10-CM codes: C43.0 – C43.9 Malignant melanoma</td>
</tr>
</tbody>
</table>

The information provided in this document is of a general nature and for informational purposes only; it is not intended to be comprehensive or instructive. Coding and coverage policies change periodically and often without warning. The healthcare provider is solely responsible for determining coverage and reimbursement parameters and appropriate coding for his/her own patients and procedures. In no way should the information provided in this section be considered a guarantee of coverage or reimbursement for any product or service.

Contact Amgen Assist 360™ at 1-888-4ASSIST or visit www.AmgenAssist360.com

IMPORTANT SAFETY INFORMATION

- Do not administer IMLYGIC® to immunocompromised patients, including those with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy, due to the risk of life-threatening disseminated herpetic infection.
- Do not administer IMLYGIC® to pregnant patients.

Please see Important Safety Information on page 5.
Please see Important Safety Information on page 5.
This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.
CODING AND BILLING CONSIDERATIONS FOR IMLYGIC®

Billing System

Update billing systems with appropriate billing codes, which may include:
- Updating billing software with the new HCPCS code and appropriate billing unit
- NDC numbers for both dosing concentrations of IMLYGIC®
- CPT codes for intralesional injections
- CPT code for ultrasonic guidance for needle placement

Consider establishing a process for integrating billing systems with additional clinical information, including:
- Number of lesions injected with IMLYGIC® during the visit to help select an appropriate CPT code (ie, ≤7 vs >7 injections)
- Volume of IMLYGIC® used during the visit to help identify appropriate billing units and to document unused drug, if required by payer (ie, volume injected vs volume discarded)

Information that may help billing staff includes:
- Billing considerations for initial vs subsequent doses of IMLYGIC®
- Coding and billing requirements for ultrasound guidance

Claim Submission

Contact Amgen Assist 360™ or call the local payer to check specific coding and billing requirements. Consider the following:
- Confirm payer[s] have updated their system with the new HCPCS code
- Billing documentation requirements for discarded volume of IMLYGIC®

Confirm appropriate documentation in the patient’s medical record, which may include:
- Clinical documentation to support appropriate E&M code
- Number and location of lesions injected with IMLYGIC® during the visit
- Time of injection[s] for IMLYGIC® and corresponding clinician’s signature

References

The information provided in this Billing and Coding Considerations sheet is of a general nature and for informational purposes only; it is not intended to be comprehensive or instructive. Coding and coverage policies change periodically and often without warning. The healthcare provider is solely responsible for determining coverage and reimbursement parameters and appropriate coding for his/her own patients and procedures. In no way should the information provided in this section be considered a guarantee of coverage or reimbursement for any product or service.

Please see Important Safety Information on page 5.
INDICATION AND IMPORTANT SAFETY INFORMATION

Indication
IMLYGIC® is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. **Limitations of use:** IMLYGIC® has not been shown to improve overall survival or have an effect on visceral metastases.

IMPORTANT SAFETY INFORMATION

Contraindications
• Do not administer IMLYGIC® to immunocompromised patients, including those with a history of primary or acquired immunodeficiency states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy, due to the risk of life-threatening disseminated herpetic infection.
• Do not administer IMLYGIC® to pregnant patients.

Warnings and Precautions
• **Accidental exposure to IMLYGIC®** may lead to transmission of IMLYGIC® and herpetic infection, including during preparation and administration. Health care providers, close contacts, pregnant women, and newborns should avoid direct contact with injected lesions, dressings, or body fluids of treated patients. The affected area in exposed individuals should be cleaned thoroughly with soap and water and/or a disinfectant.

• Caregivers should wear protective gloves when assisting patients in applying or changing occlusive dressings and observe safety precautions for disposal of used dressings, gloves, and cleaning materials. Exposed individuals should clean the affected area thoroughly with soap and water and/or a disinfectant.

• To prevent possible inadvertent transfer of IMLYGIC® to other areas of the body, patients should be advised to avoid touching or scratching injection sites or occlusive dressings.

• **Herpetic infections:** Herpetic infections (including cold sores and herpetic keratitis) have been reported in IMLYGIC®-treated patients. Disseminated herpetic infection may also occur in immunocompromised patients. Patients who develop suspicious herpes-like lesions should follow standard hygienic practices to prevent viral transmission.

• Patients or close contacts with suspected signs or symptoms of a herpetic infection should contact their health care provider to evaluate the lesions. Suspected herpetic lesions should be reported to Amgen at 1-855-IMLYGIC (1-855-465-9442). Patients or close contacts have the option of follow-up testing for further characterization of the infection.

• IMLYGIC® is sensitive to acyclovir. Acyclovir or other antiviral agents may interfere with the effectiveness of IMLYGIC®. Consider the risks and benefits of IMLYGIC® treatment before administering antiviral agents to manage herpetic infection.

• **Injection Site Complications:** Necrosis or ulceration of tumor tissue may occur during IMLYGIC® treatment. Cellulitis and systemic bacterial infection have been reported in clinical studies. Careful wound care and infection precautions are recommended, particularly if tissue necrosis results in open wounds.

• Impaired healing at the injection site has been reported. IMLYGIC® may increase the risk of impaired healing in patients with underlying risk factors [eg, previous radiation at the injection site or lesions in poorly vascularized areas]. If there is persistent infection or delayed healing of the injection site, consider the risks and benefits of continuing treatment.

• **Immune-Mediated events** including glomerulonephritis, vasculitis, pneumonitis, worsening psoriasis, and vitiligo have been reported in patients treated with IMLYGIC®. Consider the risks and benefits of IMLYGIC® before initiating treatment in patients who have underlying autoimmune disease or before continuing treatment in patients who develop immune-mediated events.

• **Plasmacytoma at the Injection Site:** Plasmacytoma in proximity to the injection site has been reported in patients with smoldering multiple myeloma after IMLYGIC® administration in a clinical study. Consider the risks and benefits of IMLYGIC® in patients with multiple myeloma or in whom plasmacytoma develops during treatment.

• **Obstructive Airway Disorder:** Obstructive airway disorder has been reported following IMLYGIC® treatment. Use caution when injecting lesions close to major airways.

Adverse Reactions
• The most commonly reported adverse drug reactions [≥ 25%] in IMLYGIC®-treated patients were fatigue, chills, pyrexia, nausea, influenza-like illness, and injection site pain. Pyrexia, chills, and influenza-like illness can occur at any time during IMLYGIC® treatment, but were more frequent during the first 3 months of treatment.
• The most common Grade 3 or higher adverse reaction was cellulitis.

Please click here to see full Prescribing Information and Medication Guide for IMLYGIC®.